The Utility of Drug Repurposing in Orphan Disease Research

Michael Murphy, MD, PhD | Jasna Klicic Badoux PhD | Erin Griner PhD | Matthew Confeld PharmD PhD

Have you considered repurposing your existing approved drug for a rare disease indication? This strategy is significantly cheaper and far less time-consuming that traditional drug development, and it produces a viable treatment option for patients in a new indication. For a comprehensive take on why repurposing is a strong development strategy, approaches for it, and challenges to be considered, check out this white paper.

Your form has been successfully submitted! Click the button below to access.
Read more
Michael Murphy, MD, PhD
Meet the author

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
Learn more